カテゴリー： 世界, 医療/バイオ, Allied Market Research

世界のパーキンソン病治療薬市場2021年-2031年：薬剤クラス別（デカルボキシラーゼ阻害剤、ドーパミン作動薬、COMT阻害剤、MAO-B阻害剤、その他）、投与経路別（経口、注射、外用）、年齢層別（50歳以下、50歳以上）

【英語タイトル】Parkinson's Disease Drugs Market by Drug Class (Decarboxylase Inhibitors, Dopamine Agonists, COMT Inhibitors, MAO-B Inhibitors, Others), by Route of Administration (Oral, Injection, Transdermal), by Age Group (50 or below 50, Above 50 years): Global Opportunity Analysis and Industry Forecast, 2021-2031

Allied Market Researchが出版した調査資料（ALD23MY039）・商品コード：ALD23MY039
・発行会社（調査会社）：Allied Market Research
・発行日：2022年9月
・ページ数：251
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後24時間以内）
・調査対象地域：グローバル
・産業分野：医薬品
◆販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥542,640見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥870,960見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,459,200見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

Allied Market Research社は、2021年には5,689.12百万ドルであった世界のパーキンソン病治療薬市場規模が2031年には10,402.65百万ドルへ上り、予測期間中（2021年～2031年）に年平均6.2％成長すると予測しています。本書では、パーキンソン病治療薬の世界市場を調査対象とし、イントロダクション、エグゼクティブサマリー、市場概要、薬剤クラス別（デカルボキシラーゼ阻害剤、ドーパミン作動薬、COMT阻害剤、MAO-B阻害剤、その他）分析、投与経路別（経口、注射、外用）分析、年齢層別（50歳以下、50歳以上）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米/中東・アフリカ）分析、競争状況、企業情報などの項目をまとめました。また、市場調査の対象企業には、AbbVie Inc., 、Amneal Pharmaceuticals, Inc.,、Biogen Inc.,、C.H. Boehringer Sohn Ko. KG,、Eli Lilly and Company,、Gentech Healthcare,、GlaxoSmithKline Plc,などが含まれています。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界のパーキンソン病治療薬市場規模：薬剤クラス別
- デカルボキシラーゼ阻害剤の市場規模
- ドーパミン作動薬の市場規模
- COMT阻害剤の市場規模
- MAO-B阻害剤の市場規模
- その他パーキンソン病治療薬の市場規模
・世界のパーキンソン病治療薬市場規模：投与経路別
- 経口における市場規模
- 注射における市場規模
- 外用における市場規模
・世界のパーキンソン病治療薬市場規模：年齢層別
- 50歳以下における市場規模
- 50歳以上における市場規模
・世界のパーキンソン病治療薬市場規模：地域別
- 北米のパーキンソン病治療薬市場規模
- ヨーロッパのパーキンソン病治療薬市場規模
- アジア太平洋のパーキンソン病治療薬市場規模
- 中南米/中東・アフリカのパーキンソン病治療薬市場規模
・競争状況
・企業情報

世界のパーキンソン病治療薬市場は、2021年に56億8,912万ドルと評価され、2021年から2031年まで年平均成長率6.2%で成長して2031年には104億2,265万ドルに達すると予測されています。
パーキンソン病は、脳の黒質領域にある少数の特定の神経細胞（ニューロン）が侵される、ゆっくりと進行する神経疾患です。これらの細胞は、脳内の信号を伝達する化学物質であるドーパミンを生成します。ドーパミンは体の動きをコントロールするのに不可欠で、パーキンソン病の多くの症状の原因はドーパミンレベルの低下です。パーキンソン病の罹患者は50歳以上がほとんどです。さらに、精神的・行動的な変化、睡眠障害、うつ病、記憶障害、疲労感などを経験することがあります。パーキンソン病治療薬は、パーキンソン病を治療し、パーキンソン病の症状を軽減するために使用されます。パーキンソン病の徴候や症状は、振戦、徐脈、筋肉の硬直、姿勢やバランスの障害などです。症状の多くは神経細胞の消失によるものです。主な危険因子は年齢で、その他に環境因子、遺伝、性別、毒素への暴露などがあります。

高齢者人口の増加やパーキンソン病患者の有病率の上昇により、パーキンソン病治療薬に対する需要の増加といった主な主要因は、予測期間中に世界的に増加すると予想されています。さらに、主要企業によるパーキンソン病治療薬の研究開発への投資が増加していることも、世界的な市場の成長を後押ししています。しかし、パーキンソン病治療薬に関連する有害事象や、パーキンソン病に関連する高額な治療費は、市場の成長を制限する可能性があります。逆に、未開拓の新興国における高い成長の可能性や、パーキンソン病治療薬の研究開発の増加、継続的な医薬品承認と製品上市は、市場の主要プレーヤーに有利な成長機会を提供すると期待されています。

パーキンソン病治療薬市場は、薬剤クラス、投与経路、年齢層、地域によって区分されます。
薬剤クラス別では、市場は脱炭酸酵素阻害薬、ドパミン作動薬、COMT阻害薬、MAO-B阻害薬、その他に分類されます。
投与経路別では、経口剤、注射剤、経皮剤に分類されます。
年齢層別では、50歳以下と50歳以上に分類されます。
地域別では、北米、欧州、アジア太平洋、LAMEAに分類されます。

本レポートに掲載されている主要企業には、AbbVie Inc.、Amneal Pharmaceuticals Inc.、Cantata Bio、Biogen Inc.、C.H. Boehringer Sohn Ko.KG、Eli Lilly company、Glaxosmithkline Plc、Gentech Healthcare、Intas Pharmaceuticals Limited、Orion Corporation、Novartis AG、Pfizer Inc.、Square group、Sun Pharmaceutical Industries Limited、Teva Pharmaceuticals、Torrent Group、UCB pharma、Viatris Inc.などがあります。

〈ステークホルダーにとっての主なメリット〉
– 本調査では、世界の空間ゲノミクスおよびトランスクリプトミクス市場を、現在の動向と将来予測とともに詳細に分析し、差し迫った投資ポケットを解明します。
– 市場成長を促進および制限する要因の包括的な分析を提供します。
– 2020年から2030年までの業界の包括的な定量分析を提供し、利害関係者が優勢な市場機会を活用できるようにします。
– 業界の主要セグメントに関する広範な分析は、世界中で使用されている空間ゲノミクスとトランスクリプトミクスのアプリケーションと製品の理解に役立ちます。
– 市場の競争展望を理解するために、主要な市場プレーヤーとその戦略を分析しています。

〈主要市場セグメント〉
薬剤クラス別
* 脱炭酸酵素阻害剤
* ドーパミン作動薬
* COMT阻害剤
* MAO-B阻害剤
* その他

投与経路別
* 経口剤
* 注射剤
* 経皮剤

年齢層別
* 50歳以下
* 50歳以上

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: PARKINSON’S DISEASE DRUGS MARKET, BY DRUG CLASS
4.1 Overview
4.1.1 Market size and forecast
4.2 Decarboxylase Inhibitors
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.2.4 Decarboxylase Inhibitors Parkinson’s Disease Drugs Market by Distribution Channel
4.2.4.1 Hospital Pharmacies Market size and forecast, by region
4.2.4.2 Drug stores and Retail Pharmacies Market size and forecast, by region
4.2.4.3 Online Providers Market size and forecast, by region
4.3 Dopamine Agonists
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 COMT Inhibitors
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 MAO-B Inhibitors
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
4.6 Others
4.6.1 Key market trends, growth factors and opportunities
4.6.2 Market size and forecast, by region
4.6.3 Market analysis by country
CHAPTER 5: PARKINSON’S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION
5.1 Overview
5.1.1 Market size and forecast
5.2 Oral
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Injection
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Transdermal
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
CHAPTER 6: PARKINSON’S DISEASE DRUGS MARKET, BY AGE GROUP
6.1 Overview
6.1.1 Market size and forecast
6.2 50 or below 50
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Above 50 years
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
CHAPTER 7: PARKINSON’S DISEASE DRUGS MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Drug Class
7.2.2.1 North America Decarboxylase Inhibitors Parkinson’s Disease Drugs Market by Distribution Channel
7.2.3 North America Market size and forecast, by Route of Administration
7.2.4 North America Market size and forecast, by Age Group
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Drug Class
7.2.5.1.2 Market size and forecast, by Route of Administration
7.2.5.1.3 Market size and forecast, by Age Group
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Drug Class
7.2.5.2.2 Market size and forecast, by Route of Administration
7.2.5.2.3 Market size and forecast, by Age Group
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Drug Class
7.2.5.3.2 Market size and forecast, by Route of Administration
7.2.5.3.3 Market size and forecast, by Age Group
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Drug Class
7.3.2.1 Europe Decarboxylase Inhibitors Parkinson’s Disease Drugs Market by Distribution Channel
7.3.3 Europe Market size and forecast, by Route of Administration
7.3.4 Europe Market size and forecast, by Age Group
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Drug Class
7.3.5.1.2 Market size and forecast, by Route of Administration
7.3.5.1.3 Market size and forecast, by Age Group
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Drug Class
7.3.5.2.2 Market size and forecast, by Route of Administration
7.3.5.2.3 Market size and forecast, by Age Group
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Drug Class
7.3.5.3.2 Market size and forecast, by Route of Administration
7.3.5.3.3 Market size and forecast, by Age Group
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Drug Class
7.3.5.4.2 Market size and forecast, by Route of Administration
7.3.5.4.3 Market size and forecast, by Age Group
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Drug Class
7.3.5.5.2 Market size and forecast, by Route of Administration
7.3.5.5.3 Market size and forecast, by Age Group
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Drug Class
7.3.5.6.2 Market size and forecast, by Route of Administration
7.3.5.6.3 Market size and forecast, by Age Group
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Drug Class
7.4.2.1 Asia-Pacific Decarboxylase Inhibitors Parkinson’s Disease Drugs Market by Distribution Channel
7.4.3 Asia-Pacific Market size and forecast, by Route of Administration
7.4.4 Asia-Pacific Market size and forecast, by Age Group
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Drug Class
7.4.5.1.2 Market size and forecast, by Route of Administration
7.4.5.1.3 Market size and forecast, by Age Group
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Drug Class
7.4.5.2.2 Market size and forecast, by Route of Administration
7.4.5.2.3 Market size and forecast, by Age Group
7.4.5.3 India
7.4.5.3.1 Market size and forecast, by Drug Class
7.4.5.3.2 Market size and forecast, by Route of Administration
7.4.5.3.3 Market size and forecast, by Age Group
7.4.5.4 Australia
7.4.5.4.1 Market size and forecast, by Drug Class
7.4.5.4.2 Market size and forecast, by Route of Administration
7.4.5.4.3 Market size and forecast, by Age Group
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Drug Class
7.4.5.5.2 Market size and forecast, by Route of Administration
7.4.5.5.3 Market size and forecast, by Age Group
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Drug Class
7.4.5.6.2 Market size and forecast, by Route of Administration
7.4.5.6.3 Market size and forecast, by Age Group
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Drug Class
7.5.2.1 LAMEA Decarboxylase Inhibitors Parkinson’s Disease Drugs Market by Distribution Channel
7.5.3 LAMEA Market size and forecast, by Route of Administration
7.5.4 LAMEA Market size and forecast, by Age Group
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Drug Class
7.5.5.1.2 Market size and forecast, by Route of Administration
7.5.5.1.3 Market size and forecast, by Age Group
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Drug Class
7.5.5.2.2 Market size and forecast, by Route of Administration
7.5.5.2.3 Market size and forecast, by Age Group
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Drug Class
7.5.5.3.2 Market size and forecast, by Route of Administration
7.5.5.3.3 Market size and forecast, by Age Group
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Drug Class
7.5.5.4.2 Market size and forecast, by Route of Administration
7.5.5.4.3 Market size and forecast, by Age Group
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 AbbVie Inc.
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Amneal Pharmaceuticals, Inc.
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Biogen Inc.
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 C.H. Boehringer Sohn Ko. KG
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Eli Lilly and Company
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Gentech Healthcare
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 GlaxoSmithKline Plc
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Intas Pharmaceuticals Limited
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Novartis AG
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Orion Corporation
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
9.11 Pfizer Inc.
9.11.1 Company overview
9.11.2 Company snapshot
9.11.3 Operating business segments
9.11.4 Product portfolio
9.11.5 Business performance
9.11.6 Key strategic moves and developments
9.12 Square group
9.12.1 Company overview
9.12.2 Company snapshot
9.12.3 Operating business segments
9.12.4 Product portfolio
9.12.5 Business performance
9.12.6 Key strategic moves and developments
9.13 Sun Pharmaceutical Industries
9.13.1 Company overview
9.13.2 Company snapshot
9.13.3 Operating business segments
9.13.4 Product portfolio
9.13.5 Business performance
9.13.6 Key strategic moves and developments
9.14 Teva Pharmaceuticals
9.14.1 Company overview
9.14.2 Company snapshot
9.14.3 Operating business segments
9.14.4 Product portfolio
9.14.5 Business performance
9.14.6 Key strategic moves and developments
9.15 Torrent Group
9.15.1 Company overview
9.15.2 Company snapshot
9.15.3 Operating business segments
9.15.4 Product portfolio
9.15.5 Business performance
9.15.6 Key strategic moves and developments
9.16 UCB
9.16.1 Company overview
9.16.2 Company snapshot
9.16.3 Operating business segments
9.16.4 Product portfolio
9.16.5 Business performance
9.16.6 Key strategic moves and developments
9.17 Viatris Inc.
9.17.1 Company overview
9.17.2 Company snapshot
9.17.3 Operating business segments
9.17.4 Product portfolio
9.17.5 Business performance
9.17.6 Key strategic moves and developments

LIST OF TABLES
TABLE 1. GLOBAL PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 2. PARKINSON'S DISEASE DRUGS MARKET SIZE, FOR DECARBOXYLASE INHIBITORS, BY REGION, 2021-2031 ($MILLION)
TABLE 3. PARKINSON'S DISEASE DRUGS MARKET FOR DECARBOXYLASE INHIBITORS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. GLOBAL DECARBOXYLASE INHIBITORS PARKINSON'S DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 5. PARKINSON'S DISEASE DRUGS MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 6. PARKINSON'S DISEASE DRUGS MARKET, FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 7. PARKINSON'S DISEASE DRUGS MARKET, FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
TABLE 8. PARKINSON'S DISEASE DRUGS MARKET SIZE, FOR DOPAMINE AGONISTS, BY REGION, 2021-2031 ($MILLION)
TABLE 9. PARKINSON'S DISEASE DRUGS MARKET FOR DOPAMINE AGONISTS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 10. PARKINSON'S DISEASE DRUGS MARKET SIZE, FOR COMT INHIBITORS, BY REGION, 2021-2031 ($MILLION)
TABLE 11. PARKINSON'S DISEASE DRUGS MARKET FOR COMT INHIBITORS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 12. PARKINSON'S DISEASE DRUGS MARKET SIZE, FOR MAO-B INHIBITORS, BY REGION, 2021-2031 ($MILLION)
TABLE 13. PARKINSON'S DISEASE DRUGS MARKET FOR MAO-B INHIBITORS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 14. PARKINSON'S DISEASE DRUGS MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 15. PARKINSON'S DISEASE DRUGS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 16. GLOBAL PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 17. PARKINSON'S DISEASE DRUGS MARKET SIZE, FOR ORAL, BY REGION, 2021-2031 ($MILLION)
TABLE 18. PARKINSON'S DISEASE DRUGS MARKET FOR ORAL, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 19. PARKINSON'S DISEASE DRUGS MARKET SIZE, FOR INJECTION, BY REGION, 2021-2031 ($MILLION)
TABLE 20. PARKINSON'S DISEASE DRUGS MARKET FOR INJECTION, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 21. PARKINSON'S DISEASE DRUGS MARKET SIZE, FOR TRANSDERMAL, BY REGION, 2021-2031 ($MILLION)
TABLE 22. PARKINSON'S DISEASE DRUGS MARKET FOR TRANSDERMAL, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 23. GLOBAL PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 24. PARKINSON'S DISEASE DRUGS MARKET SIZE, FOR 50 OR BELOW 50, BY REGION, 2021-2031 ($MILLION)
TABLE 25. PARKINSON'S DISEASE DRUGS MARKET FOR 50 OR BELOW 50, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 26. PARKINSON'S DISEASE DRUGS MARKET SIZE, FOR ABOVE 50 YEARS, BY REGION, 2021-2031 ($MILLION)
TABLE 27. PARKINSON'S DISEASE DRUGS MARKET FOR ABOVE 50 YEARS, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 28. PARKINSON'S DISEASE DRUGS MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 29. NORTH AMERICA PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 30. NORTH AMERICA DECARBOXYLASE INHIBITORS PARKINSON'S DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 31. NORTH AMERICA PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 32. NORTH AMERICA PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 33. NORTH AMERICA PARKINSON'S DISEASE DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 34. U.S. PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 35. U.S. PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 36. U.S. PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 37. CANADA PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 38. CANADA PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 39. CANADA PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 40. MEXICO PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 41. MEXICO PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 42. MEXICO PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 43. EUROPE PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 44. EUROPE DECARBOXYLASE INHIBITORS PARKINSON'S DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 45. EUROPE PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 46. EUROPE PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 47. EUROPE PARKINSON'S DISEASE DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 48. GERMANY PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 49. GERMANY PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 50. GERMANY PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 51. FRANCE PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 52. FRANCE PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 53. FRANCE PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 54. UK PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 55. UK PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 56. UK PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 57. ITALY PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 58. ITALY PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 59. ITALY PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 60. SPAIN PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 61. SPAIN PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 62. SPAIN PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 63. REST OF EUROPE PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 64. REST OF EUROPE PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 65. REST OF EUROPE PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 66. ASIA-PACIFIC PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 67. ASIA-PACIFIC DECARBOXYLASE INHIBITORS PARKINSON'S DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 68. ASIA-PACIFIC PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 69. ASIA-PACIFIC PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 70. ASIA-PACIFIC PARKINSON'S DISEASE DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 71. JAPAN PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 72. JAPAN PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 73. JAPAN PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 74. CHINA PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 75. CHINA PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 76. CHINA PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 77. INDIA PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 78. INDIA PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 79. INDIA PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 80. AUSTRALIA PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 81. AUSTRALIA PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 82. AUSTRALIA PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 83. SOUTH KOREA PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 84. SOUTH KOREA PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 85. SOUTH KOREA PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 86. REST OF ASIA-PACIFIC PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 87. REST OF ASIA-PACIFIC PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 88. REST OF ASIA-PACIFIC PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 89. LAMEA PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 90. LAMEA DECARBOXYLASE INHIBITORS PARKINSON'S DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 91. LAMEA PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 92. LAMEA PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 93. LAMEA PARKINSON'S DISEASE DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 94. BRAZIL PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 95. BRAZIL PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 96. BRAZIL PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 97. SAUDI ARABIA PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 98. SAUDI ARABIA PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 99. SAUDI ARABIA PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 100. SOUTH AFRICA PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 101. SOUTH AFRICA PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 102. SOUTH AFRICA PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 103. REST OF LAMEA PARKINSON'S DISEASE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
TABLE 104. REST OF LAMEA PARKINSON'S DISEASE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
TABLE 105. REST OF LAMEA PARKINSON'S DISEASE DRUGS MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
TABLE 106.ABBVIE INC.: COMPANY SNAPSHOT
TABLE 107.ABBVIE INC.: OPERATING SEGMENTS
TABLE 108.ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 109.ABBVIE INC.: NET SALES,
TABLE 110.ABBVIE INC.: KEY STRATERGIES
TABLE 111.AMNEAL PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
TABLE 112.AMNEAL PHARMACEUTICALS, INC.: OPERATING SEGMENTS
TABLE 113.AMNEAL PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
TABLE 114.AMNEAL PHARMACEUTICALS, INC.: NET SALES,
TABLE 115.AMNEAL PHARMACEUTICALS, INC.: KEY STRATERGIES
TABLE 116.BIOGEN INC.: COMPANY SNAPSHOT
TABLE 117.BIOGEN INC.: OPERATING SEGMENTS
TABLE 118.BIOGEN INC.: PRODUCT PORTFOLIO
TABLE 119.BIOGEN INC.: NET SALES,
TABLE 120.BIOGEN INC.: KEY STRATERGIES
TABLE 121.C.H. BOEHRINGER SOHN KO. KG: COMPANY SNAPSHOT
TABLE 122.C.H. BOEHRINGER SOHN KO. KG: OPERATING SEGMENTS
TABLE 123.C.H. BOEHRINGER SOHN KO. KG: PRODUCT PORTFOLIO
TABLE 124.C.H. BOEHRINGER SOHN KO. KG: NET SALES,
TABLE 125.C.H. BOEHRINGER SOHN KO. KG: KEY STRATERGIES
TABLE 126.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 127.ELI LILLY AND COMPANY: OPERATING SEGMENTS
TABLE 128.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 129.ELI LILLY AND COMPANY: NET SALES,
TABLE 130.ELI LILLY AND COMPANY: KEY STRATERGIES
TABLE 131.GENTECH HEALTHCARE: COMPANY SNAPSHOT
TABLE 132.GENTECH HEALTHCARE: OPERATING SEGMENTS
TABLE 133.GENTECH HEALTHCARE: PRODUCT PORTFOLIO
TABLE 134.GENTECH HEALTHCARE: NET SALES,
TABLE 135.GENTECH HEALTHCARE: KEY STRATERGIES
TABLE 136.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 137.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
TABLE 138.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 139.GLAXOSMITHKLINE PLC: NET SALES,
TABLE 140.GLAXOSMITHKLINE PLC: KEY STRATERGIES
TABLE 141.INTAS PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT
TABLE 142.INTAS PHARMACEUTICALS LIMITED: OPERATING SEGMENTS
TABLE 143.INTAS PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO
TABLE 144.INTAS PHARMACEUTICALS LIMITED: NET SALES,
TABLE 145.INTAS PHARMACEUTICALS LIMITED: KEY STRATERGIES
TABLE 146.NOVARTIS AG: COMPANY SNAPSHOT
TABLE 147.NOVARTIS AG: OPERATING SEGMENTS
TABLE 148.NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 149.NOVARTIS AG: NET SALES,
TABLE 150.NOVARTIS AG: KEY STRATERGIES
TABLE 151.ORION CORPORATION: COMPANY SNAPSHOT
TABLE 152.ORION CORPORATION: OPERATING SEGMENTS
TABLE 153.ORION CORPORATION: PRODUCT PORTFOLIO
TABLE 154.ORION CORPORATION: NET SALES,
TABLE 155.ORION CORPORATION: KEY STRATERGIES
TABLE 156.PFIZER INC.: COMPANY SNAPSHOT
TABLE 157.PFIZER INC.: OPERATING SEGMENTS
TABLE 158.PFIZER INC.: PRODUCT PORTFOLIO
TABLE 159.PFIZER INC.: NET SALES,
TABLE 160.PFIZER INC.: KEY STRATERGIES
TABLE 161.SQUARE GROUP: COMPANY SNAPSHOT
TABLE 162.SQUARE GROUP: OPERATING SEGMENTS
TABLE 163.SQUARE GROUP: PRODUCT PORTFOLIO
TABLE 164.SQUARE GROUP: NET SALES,
TABLE 165.SQUARE GROUP: KEY STRATERGIES
TABLE 166.SUN PHARMACEUTICAL INDUSTRIES: COMPANY SNAPSHOT
TABLE 167.SUN PHARMACEUTICAL INDUSTRIES: OPERATING SEGMENTS
TABLE 168.SUN PHARMACEUTICAL INDUSTRIES: PRODUCT PORTFOLIO
TABLE 169.SUN PHARMACEUTICAL INDUSTRIES: NET SALES,
TABLE 170.SUN PHARMACEUTICAL INDUSTRIES: KEY STRATERGIES
TABLE 171.TEVA PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 172.TEVA PHARMACEUTICALS: OPERATING SEGMENTS
TABLE 173.TEVA PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 174.TEVA PHARMACEUTICALS: NET SALES,
TABLE 175.TEVA PHARMACEUTICALS: KEY STRATERGIES
TABLE 176.TORRENT GROUP: COMPANY SNAPSHOT
TABLE 177.TORRENT GROUP: OPERATING SEGMENTS
TABLE 178.TORRENT GROUP: PRODUCT PORTFOLIO
TABLE 179.TORRENT GROUP: NET SALES,
TABLE 180.TORRENT GROUP: KEY STRATERGIES
TABLE 181.UCB: COMPANY SNAPSHOT
TABLE 182.UCB: OPERATING SEGMENTS
TABLE 183.UCB: PRODUCT PORTFOLIO
TABLE 184.UCB: NET SALES,
TABLE 185.UCB: KEY STRATERGIES
TABLE 186.VIATRIS INC.: COMPANY SNAPSHOT
TABLE 187.VIATRIS INC.: OPERATING SEGMENTS
TABLE 188.VIATRIS INC.: PRODUCT PORTFOLIO
TABLE 189.VIATRIS INC.: NET SALES,
TABLE 190.VIATRIS INC.: KEY STRATERGIES

★調査レポート[世界のパーキンソン病治療薬市場2021年-2031年：薬剤クラス別（デカルボキシラーゼ阻害剤、ドーパミン作動薬、COMT阻害剤、MAO-B阻害剤、その他）、投与経路別（経口、注射、外用）、年齢層別（50歳以下、50歳以上）] (コード：ALD23MY039)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のパーキンソン病治療薬市場2021年-2031年：薬剤クラス別（デカルボキシラーゼ阻害剤、ドーパミン作動薬、COMT阻害剤、MAO-B阻害剤、その他）、投与経路別（経口、注射、外用）、年齢層別（50歳以下、50歳以上）]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界のジストニア治療薬市場2021-2031：薬剤種類別（ドーパミン作動薬、GABA作用薬、抗けいれん薬、その他）、投与経路別（経口、注射）、流通チャネル別（病院内薬局、オンラインプロバイダー、ドラッグストア・小売薬局）
  • 世界の胃がん市場2021年-2031年：疾患種類別（腺がん、リンパ腫、消化管間質腫瘍、カルチノイド腫瘍、その他）、治療種類別（免疫療法、標的療法、化学療法、放射線療法＆外科）、薬剤クラス別（PD-1/PD-L1阻害剤、HER2アンタゴニスト、VEGFR2アンタゴニスト、その他）、投与経路別（経口、注射剤）、流通チャネル別（病院薬局、専門薬局＆小売薬局、その他）
  • 世界のインクレチン系薬剤市場2023年-2032年：薬剤クラス別（GLP-1受容体作動薬、DPP-4阻害薬）、投与経路別（非経口、経口）、流通チャネル別（病院薬局、ドラッグストア・小売薬局、オンラインプロバイダー）
  • 世界の抗血小板剤市場2023年-2032年：薬剤クラス別（アデノシン二リン酸（ADP）受容体阻害剤、非可逆的阻害剤シクロオキシゲナーゼ、その他）、投与経路別（経口剤、注射剤）、流通経路別（病院薬局、ドラッグストア・小売薬局、オンラインプロバイダー）
  • 日本の重症筋無力症治療薬市場2023年-2032年：薬剤クラス別（モノクローナル抗体、静注用免疫グロブリン、その他）、年齢層別（55歳以下、55歳以上）、流通チャネル別（病院薬局、ドラッグストア＆小売薬局、オンラインプロバイダー）
  • 世界の重症筋無力症治療市場2023年-2032年：薬剤クラス別（モノクローナル抗体、静脈内免疫グロブリン、その他）、年齢層別（55歳以下、55歳以上）、流通チャネル別（病院薬局、ドラッグストア＆小売薬局、オンラインプロバイダー）

    • ◆H&Iグローバルリサーチのお客様（例）◆